Table 2.
Treatment history prior to talimogene laherparepvec administration
| Treatment history before initiating T-VEC | Austria, Germany, UK (n = 35) | Netherlands (n = 31) | Total (N = 66) |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Surgery, N (%) | 35 (100) | 31 (100) | 66 (100) |
| Type of surgery, n (%) | |||
| Recorded resection of recurrent disease | 17 (48.6) | 21 (67.7) | 38 (57.6) |
| Sentinel biopsy | 18 (51.4) | 9 (29.0) | 27 (40.9) |
| Lymphadenectomy | 17 (48.6) | 7 (22.6) | 24 (36.4) |
| No. of resections for recurrent disease per patient, median (IQR; range) | 3.0 (1, 4; 1–11) | 1.0 (1, 3; 1–10) | 2.0 (1, 4; 1–11) |
| Months from most recent resection for recurrent disease to initiating T-VEC, median (IQR; range) | 10.0 (4, 22; 2–77) | 6.2 (4, 11; 2–45) | 7.4 (4, 15; 2–77) |
| Adjuvant therapy, N (%) | 12 (34.3) | 0 | 12 (18.2) |
| Local (intralesional therapy injection of IL-2 or IFNα) | 3 (25.0) | 0 | 3 (25.0) |
| Systemic (IFNα) | 12 (100) | 0 | 12 (100) |
| Locoregional therapy, N (%) | 17 (48.6) | 12 (38.7) | 29 (43.9) |
| Radiation therapy | 14 (82.4) | 1 (8.3) | 15 (51.7) |
| Local ablation therapy | 1 (5.9)a | 5 (41.7) | 6 (20.7) |
| Electrochemotherapy | 4 (23.5)a | 0 | 4 (13.8) |
| Isolated limb perfusion | 2 (11.8)a | 9 (75.0) | 11 (37.9) |
| Intralesional therapy injection of IL-2 or IFNα | 3 (17.6)a | 0 | 3 (10.3) |
| Topical imiquimod | 1 (5.9)b | 0 | 1 (3.4) |
| Other | 1 (5.9)c | 0 | 1 (3.4) |
| Systemic therapy, N (%) | 21 (60.0) | 2 (6.5) | 23 (34.8) |
| IFNα | 12 (57.1) | 0 | 12 (52.2) |
| Pembrolizumab | 8 (38.1) | 2 (100) | 10 (43.5) |
| Ipilimumab | 8 (38.1) | 0 | 8 (34.8) |
| Chemotherapyd | 7 (33.3) | 0 | 7 (30.4) |
| IL-2 | 3 (14.3) | 0 | 3 (13.0) |
| Nivolumab | 3 (14.3) | 0 | 3 (13.0) |
| Dabrafenib | 0 | 1 (50.0) | 1 (1.5) |
| Imatinib | 1 (4.8) | 0 | 1 (4.3) |
| Ipilimumab/nivolumab | 1 (4.8) | 0 | 1 (4.3) |
| Trametinib/dabrafenib | 1 (4.8) | 0 | 1 (4.3) |
IFN interferon, IL interleukin, IQR interquartile range, T-VEC talimogene laherparepvec
aPrior treatment only in Germany
bPrior treatment only in Austria
cOther local therapy was “Chemoperfusion, left leg with melphalan” for a patient in Austria
dExamples of chemotherapies given included dacarbazine, temozolomide and taxanes